3-[2-(2-Methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4-yl]phenol | 1070733-36-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫氮卓类
• 英文名称: 3-[2-(2-Methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4-yl]phenol
• CAS: 1070733-36-6
• 化学式: C₂₂H₁₉NO₂S
• 分子量: 361.464
• InChiKey: PVYNAGGLIAVILG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  67.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (E)-1-(3-hydroxyphenyl)-3-(2-methoxyphenyl)prop-2-en-1-one 、 2-氨基苯硫醇 在 溶剂黄146 作用下， 以 甲醇 为溶剂， 生成 3-[2-(2-Methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4-yl]phenol
  参考文献：
  名称：

  Solid-phase synthesis and biological evaluation of a parallel library of 2,3-dihydro-1,5-benzothiazepines

  摘要：

  Solid-phase synthesis of a parallel library of 3'-hydroxy-2,3-dihydrobenzothiazepines has been carried out through [4+3] annulation of alpha,beta-unsaturated ketones with aminothiophenol, using Wang resin as solid support. The synthesized compounds were evaluated for their potential as antibacterial, tumor inhibitors as well as acetyl- and butyrylcholinesterase inhibitors. None of the compounds showed any significant antibacterial activity. However, quite a few compounds showed significant potential as crown gall tumor inhibitors. These results reflect a strong exploratory potential in search of new benzothiazepines as source of anticancer agents. The results of the inhibition of cholinesterase revealed that benzothiazepines have a greater potential as butyrylcholinesterase inhibitors as compared to acetylcholinesterase. Moreover, the substitution of hydroxy group at C-3 in ring A led to increased activity when compared to unsubstituted- and 2'-OH substituted benzothiazepines. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.07.009

文献信息

• In silico studies on 2,3-dihydro-1,5-benzothiazepines as cholinesterase inhibitors
  作者：Farzana Latif Ansari、Saima Kalsoom、Zaheer-ul-Haq、Zahra Ali、Farukh Jabeen

  DOI：10.1007/s00044-011-9754-6

  日期：2012.9

  In vitro studies on cholinesterase inhibitory potential on the three sets of 2,3-dihydro-1,5-benzothiazepines have been carried out. The compounds in Set 1 were unsubstituted on ring A, while those in Sets 2 and 3 had a 2'- and 3'-hydoxy substituent, respectively, in ring A. These studies revealed that they are mixed inhibitors of both AChE and BChE as reflected from their IC50 values. It was further observed that 3'-hydroxy substituted benzothiazepines (Set 3) were found to have stronger affinity for both AChE and BChE compared with those of Sets 1 and 2. Moreover, all the compounds in Set 3 were found to be stronger BChE inhibitors than AChE. These experimental observations were rationalized by conducting in silico studies using molecular docking tool of Molecular Operating Environment (MOE) software, thereby, a good correlation was observed between IC50 values and their binding interactions within the enzyme active site. We have observed that these interactions were electrostatic and hydrophobic in nature besides hydrogen bonding. The high BChE inhibitory potential of 3'-hydroxy substituted benzothiazepines was found to be cumulative effect of hydrogen bonding and pi-pi interactions between the ligand and BChE. These findings may serve as a guideline for synthesizing more potent ChE inhibitors for the treatment of Alzheimer's disease and related dementias.
• Dual inhibition of the α-glucosidase and butyrylcholinesterase studied by Molecular Field Topology Analysis
  作者：Farukh Jabeen、Polina V. Oliferenko、Alexander A. Oliferenko、Girinath G. Pillai、Farzana Latif Ansari、C. Dennis Hall、Alan R. Katritzky

  DOI：10.1016/j.ejmech.2014.04.018

  日期：2014.6

  A striking dual inhibition of enzymes α-glucosidase and butyrylcholinesterase by small drug-like molecules, including 1,4-disubstituted-1,2,3-triazoles, chalcones, and benzothiazepines, was rationalized with the help of Molecular Field Topology Analysis, a 3D QSAR technique similar to CoMFA. A common pharmacophore supported the concept of a link existing between type-2 diabetes mellitus and Alzheimer's disease. These findings will be instrumental for rational design of drug candidates for both of these conditions.